期刊
JACC-CARDIOVASCULAR INTERVENTIONS
卷 4, 期 6, 页码 654-664出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jcin.2011.02.011
关键词
bleeding; mortality; myocardial infarction; risk score
资金
- Medicines Company, Parsippany, New Jersey
- The Cardiovascular Research Foundation, New York, New York
- Boston Scientific, Natick, Massachusetts
- Bristol-Myers Squibb/Sanofi-Aventis
- The Medicines Company
- Sanofi-Aventis
- Eli Lilly
- NIH
- Pfizer
- Roche
- Johnson Johnson
- Schering-Plough
- Merck Sharpe Dohme
- AstraZeneca
- GlaxoSmithKline
- Daiichi Sankyo Pharma Development
- Bristol-Myers Squibb
- Regado Biosciences
- Servier Laboratories
- Nycomed
- Cordis
- Boston Scientific
- Medtronic
- Abbott
- Daiichi Sankyo
- Eli Lilly and Co.
- Maquet
- Boehringer Ingelheim
- Liposcience
- Merck
- Pozen, Inc.
- Gilead Sciences
- WebMD
- Kai
- Schering/Merck
- Takeda
Objectives This study sought to develop a risk score predictive of bleeding in patients undergoing percutaneous coronary intervention (PCI) and to investigate the impact of bleeding on subsequent mortality. Background Bleeding complications after PCI have been independently associated with early and late mortality. Methods This study represents a patient-level pooled analysis including 17,034 patients undergoing PCI from 3 large, randomized trials of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors, including the REPLACE-2 (Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events), ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy), and HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trials. We developed a risk score to predict noncoronary artery bypass graft (CABG)-related TIMI (Thrombolysis In Myocardial Infarction) major bleeding and evaluated the impact of various types of bleeding on 1-year mortality. Results A non-CABG-related TIMI major bleed occurred within 30 days in 267 patients (1.6%), and death occurred in 497 patients (2.9%) within 1 year. A risk score was developed to predict the bleeding risk of patients undergoing PCI, consisting of 7 variables (serum creatinine, age, sex, presentation, white blood cell count, cigarette smoking, and randomized treatment). The TIMI major bleeding rates increased by bleeding risk score groups: from 0.4% for those in the lowest to 5.8% for those in the highest risk group. Non-CABG-related TIMI major bleeding and the occurrence of myocardial infarction within 30 days were independent predictors of subsequent mortality, with respective hazard ratios of 4.2 and 2.9, each p < 0.001. Ranked in order of severity, TIMI major bleeding, blood transfusion without TIMI bleed, TIMI minor bleeding requiring blood transfusion, and TIMI minor bleeding not requiring blood transfusion were independent predictors of subsequent mortality with hazard ratios of 4.89, 2.91, 2.73, and 1.66, respectively. Isolated hematomas were not predictive of subsequent mortality. Conclusions Non-CABG-related bleeding within 30 days is strongly associated with an increased risk of subsequent mortality at 1 year in patients undergoing PCI for all indications. A risk score was established to calculate the bleeding risk for patients undergoing PCI, allowing therapeutic decision making to minimize the incidence of bleeding. (J Am Coll Cardiol Intv 2011;4:654-64) (C) 2011 by the American College of Cardiology Foundation
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据